High impact information on Pulmonary Disease (Specialty)

• Phosphodiesterase 4 inhibitors, such as Ariflo, possibly represent the most important advance in pulmonary medicine in recent years [1].
• PATIENTS AND METHODS: The 590 patients having COPD as primary disease who were hospitalized in the pneumology unit of a university hospital from 1981 to 1990 were studied [2].
• ATS Consensus Statement: Research opportunities and challenges in pediatric pulmonology [3].
• The protective effects of heme oxygenase-1 and products of its enzymatic activity, including carbon monoxide, biliverdin and bilirubin, and ferritin, have opened the door to potential therapeutic and disease-monitoring possibilities that one day may be applicable to pulmonary medicine [4].
• Genetics and pulmonary medicine. 6. Immotile cilia syndrome: past, present, and prospects for the future [5].

Biological context of Pulmonary Disease (Specialty)

• Seaprose (Flaminase, Puropharma) belongs to this class and is a proteinase from Aspergillus melleus and it is mainly used in traumatology, orthopaedics, gynaecology and pneumology [6].

Anatomical context of Pulmonary Disease (Specialty)

• METHODS: We prospectively evaluated clinical data and sputum culture results of 171 patients, admitted to the pulmonology department of the University Hospital Maastricht with an acute exacerbation of COPD from 1st January 1999 until 31st December 1999 [7].
• Controversies in pulmonary medicine. Respiratory muscle training should be instituted in all COPD patients [8].

Associations of Pulmonary Disease (Specialty) with chemical compounds

• We prospectively registered all antibiotic courses on wards for Internal Medicine, Surgery, and Pulmonology during a 2 month period, before (n = 362, inventorial phase) and after (n = 281, implementation phase) the introduction of guidelines for switching therapy [9].
• This randomised, single-blind, parallel-group study was carried out in 48 French pneumology centres to compare the anti-emetic efficacy of ondansetron and an alizapride plus methylprednisolone (ALI/MPS) combination in patients receiving high-dose cisplatin [10].
• Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: focus on warfarin and cisapride [11].
• The use of cefotaxime in pneumology [12].
• Nitric oxide has recently been introduced to the world of neonatal pulmonary medicine [13].

Gene context of Pulmonary Disease (Specialty)

• Heme oxygenase-1 and carbon monoxide in pulmonary medicine [14].
• SETTING: Department of Pulmonology, Rijnstate Hospital Arnhem, The Netherlands. PATIENTS: Fourteen stable COPD patients (7 men; median age, 71.5 years; age range, 59 to 81 years; FEV(1), 32.5% predicted; FEV(1) range, 19 to 70% predicted) participated in the study [15].
• Recommendations for long term oxygen therapy (LTOT). Report on an SEP (European Society of Pneumology) Task Group [16].
• Seventy-seven unrelated CF patients were analyzed, who were previously diagnosed and currently under treatment at the Pneumology Service of our hospital [17].
• DESIGN: One hundred seventy-five consecutive patients hospitalized in cardiac and pneumology wards underwent SCT angiography for suspected PE over a 30-month period [18].

Analytical, diagnostic and therapeutic context of Pulmonary Disease (Specialty)

• Guidelines for the management of community-acquired pneumonia in adults. Italian Society of Pneumology. Italian Society of Respiratory Medicine. Italian Society of Chemotherapy [19].

References